Provenienza dei contatti di primo grado di Etienne Eisenmann
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France.
3
| Private Company | Biotechnology | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Etienne Eisenmann tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Medical Specialties | Chief Executive Officer | |
ATYR PHARMA, INC. | Pharmaceuticals: Major | President | |
INSEAD | College/University | Masters Business Admin | |
MG Biotherapeutics LLC | Chief Operating Officer | ||
Université Paris 1 Panthéon-Sorbonne | College/University | Undergraduate Degree | |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Medical Specialties | Corporate Officer/Principal | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | Real Estate Development | Chairman | |
Groupe de Sup de Co La Rochelle | College/University | Graduate Degree | |
Epygon SASU
Epygon SASU Medical SpecialtiesHealth Technology Epygon SASU develops mitral valve instruments. It also engages in the research and development in physical and natural sciences. The company was founded by Marcio Scorsin and Enrico Pasquino on December 28, 2011 and is headquartered in Paris, France. | Medical Specialties | Founder | |
LOGICBIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Chairman | |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member | |
AFFLUENT MEDICAL | Medical Specialties | Chief Tech/Sci/R&D Officer | |
French American Chamber of Commerce New England | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Francia | 9 |
Settori
Health Technology | 12 |
Consumer Services | 4 |
Finance | 2 |
Health Services | 2 |
Posizioni
Corporate Officer/Principal | 7 |
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Chairman | 3 |
Contatti più connessi
Insiders | |
---|---|
Frédéric Chéreau | 17 |
Marcio Scorsin | 3 |
Jean-Thomas Vilquin | 1 |
- Borsa valori
- Insiders
- Etienne Eisenmann
- Connessioni Società